We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma

Source: Pharmacy Times articles OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models. Read More

The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma

Source: Pharmacy Times articles Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma. Read More

Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma

Source: Pharmacy Times articles The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma. Read More

Recent Publications

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia

Front Oncol. 2025 Jan 21;14:1535869. doi: 10.3389/fonc.2024.1535869. eCollection 2024. ABSTRACT...

Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes

Ann Hematol. 2024 Dec;103(12):5849-5859. doi: 10.1007/s00277-024-06129-5. Epub 2024 Dec 7....

Email

info@myeloma360.com